Martin Shkreli, major shareholder of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) Just Obtained Shares

Share with your friends










Submit

Martin Shkreli major shareholder of KaloBios Pharmaceuticals Just Obtained Shares-Transactions

Martin Shkreli Insider Buy Transaction

After the disclosing of a public form filled with SEC; a telling investment became apparent. The major shareholder of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) , Martin Shkreli; executed a sizable deal in the open market by accumulating 440,000 shares at the avg. market share price which was $2.0 of the public company valued at near $888,800 USD . In the last 30 days, he also bought 1.21 million shares that are worth approx $1.63 million USD. And, It’s sure Martin’s acquisition isn’t going to stay ignored as he now is having 2.07 million shares – ( 10.42 % of Kalobios Pharmaceuticals Inc’s Market Cap ).

Kalobios Pharmaceuticals Inc Stock Rating, Sentiment and Fundamentals

The investment made by Martin Shkreli shows his confidence in the Company’s future and stock price.

Rating & Sentiment
PsychSignal Social:SELL
Analysts Rating:BUY
Hedge Funds Sentiment:SELL
Stock Fundamentals
Earnings + FCF Trend:SELL
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:UP
MT Trend:UP
LT Trend:UP
OctaFinance Rating*:BUY

* Read How Our Stock Ratings System Works

Chart analysis shows Kalobios Pharmaceuticals Inc’s stock price increased 443.15 % in the last 200 days. And this upward trajectory looks stable. Now could this mean that Martin Shkreli does a fantastic job at the -listed company? Our analysts rate the -listed Kalobios Pharmaceuticals Inc’s stock “Buy”, based on our time momentum model.

Price Chart of Kalobios Pharmaceuticals NASDAQ:KBIO Stock

Martin Shkreli major shareholder of KaloBios Pharmaceuticals Just Obtained Shares-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

Should the price reach $2.28 as calculated by our medium-term target, Martin Shkreli’s net worth should increase by $427,496 U.S. Dollars. Have you thought about your own stock portfolio?

Hedge Funds Ownership

Latest 13F SEC filings disclose 17 institutional investors own Kalobios Pharmaceuticals Inc. Our tracked institutional investors have historically had a low interest in this company, and that was also the case in the last quarter. The institutional ownership was 167.40 % of the stock’s outstanding shares. Its down 22.14 % from Q1 2015. These investment managers decreased the total shares they own by 1.96 million to 6.90 million this quarter. A total of 2 funds opened new positions in Kalobios Pharmaceuticals Inc and 3 increased their holdings. There were 8 funds that closed their positions and 3 that reduced them.

HEDGE-FUNDS-LIST-DATABASE-FREE

Harbourvest Partners Llc is the most bullish institutional investor on Kalobios Pharmaceuticals Inc, with ownership of 57,604 shares as of Q2 2015 for 0.01% of the fund’s portfolio. Opus Point Partners Management Llc is another bullish institutional manager owning 746,467 shares of the company or 0.28% of their stocks portfolio. Further Hallmark Capital Management Inc have less than 0.01% of their stock portfolio invested in the stock for 15,861 shares. The California-based fund Primecap Management Co Ca revealed it had purchased a stake worth less than 0.01% of the fund’s stock portfolio in Kalobios Pharmaceuticals Inc. The Pennsylvania-based fund Valley National Advisers Inc is also upbeat about the company’s stock, with ownership of 162 shares or less than 0.01% of their stock portfolio.

KaloBios Pharmaceuticals NASDAQ:KBIO Company Profile

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of monoclonal antibody therapeutics for diseases that represent a burden to society and to patients and their families. The Company operates through the development of pharmaceutical products segment. The Company seeks to identify and develop products that may treat multiple indications through proof of concept studies. The Company’s principal pharmaceutical product candidates include: KB004, KB003 and KB001‑A. KB004 is a Humaneered anti EphA3 monoclonal antibody that has the potential to offer an approach to treating both hematologic malignancies and solid tumors. KB003 is a Humaneered anti granulocyte macrophage colony stimulating factor monoclonal antibody that was developed for the treatment of severe asthma. KB001-A is a Humaneered, PEGylated, anti PcrV modified antibody fragment antibody that was developed for the prevention and treatment of Pseudomonas aeruginosa infections.

Company Website: KaloBios Pharmaceuticals

As of writing its market cap is: $41.02 million and it has 19.82 million shares outstanding. Now there are 30.51% shareholders and the institutional ownership is 30.51%. Kalobios Pharmaceuticals Inc has 32 employees. Kalobios Pharmaceuticals Inc was filled in Delaware on 2001-09-19. The stock closed at $18.25 yesterday and it had average 2 days volume of 12858905 shares. It is up from the 30 days average shares volume of 1462299. Kalobios Pharmaceuticals Inc has a 52 weeks low of $0.44 and a one year high of $23.11. The stock price is below the 200 days SMA. Kalobios Pharmaceuticals Inc last issued its quarterly earnings information on 08/10/2015. The company reported -1.46 EPS for the quarter, above the consensus estimate of -1.68 by 0.22. The company had a revenue of for 6/30/2015 and for 3/31/2015. Therefore, the revenue was down.

* The securities reported herein are owned directly by Martin Shkreli – who is a member of a “group” for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly – Mr. Shkreli does not have a pecuniary interest in the shares owned by the other members of the group.

KaloBios Pharmaceuticals - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.